ExThera Medical yesterday said it received CE Mark approval for is Seraph 100 Microbind Affinity Blood Filter. The Seraph 100 is designed to reduce pathogens during bloodstream infections and the CE Mark allows the filter to be used as an adjunct to anti-infective therapy. ExThera’s filter quickly lowers the concentration of bacteria, viruses and fungi […]
Exthera Medical wins FDA EAP designation for Seraph 100 blood filter
Exthera Medical said today that the FDA granted its Seraph 100 blood filter an expedited access pathway designation. The approval comes with an initial indication for use “as an adjunctive treatment for bacteremia in addition to antibiotics for patients receiving hemodialysis when the source of the infection is heparin- or heparin sulfate-binding bacteria, including antibiotic […]
Exthera Medical closes $15 million Series B for Seraph blood infection filter
Updated to correct funding amounts and include new information from Exthera. By Fink Densford & Varun Saxena Martinez, Calif.-based Exthera Medical said it raised a $15.3 million Series B round following positive tests of its CE-Marked Seraph blood filter in animal studies. The company’s Seraph microbind affinity blood filter is designed to remove a range of sepsis-causing bacteria, […]
ExThera wins nod for CE Mark trial for Seraph blood filter
ExThera Medical said it won approval for a CE Mark trial for its Seraph blood filter, which is designed to remove pathogens from the bloodstream. Berkeley, Calif.-based ExThera said Germany’s Bundesinstitut für Arzneimittel und Medizinprodukte approved the protocol for a trial of the Seraph device in treating dialysis patients with Staphylococcus aureus and MRSA bloodstream infections. “Certain bloodstream […]
ExThera unveils promising data for ‘superbug’ device
ExThera Medical unveiled promising data from a study of its Seraph blood-filtering device in the treatment of drug-resistant strains of E. coli and pneumonia.
